Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 7
1992 32
1993 40
1994 38
1995 36
1996 43
1997 82
1998 173
1999 291
2000 374
2001 531
2002 630
2003 741
2004 946
2005 1276
2006 1577
2007 2003
2008 2533
2009 3011
2010 3530
2011 3999
2012 4514
2013 4818
2014 5193
2015 5540
2016 6006
2017 6677
2018 6761
2019 3319
2020 90
Text availability
Article attribute
Article type
Publication date

Search Results

56,718 results
Results by year
Filters applied: . Clear all
Page 1
Antibody humanization methods - a review and update
Safdari Y, et al. Biotechnol Genet Eng Rev 2013 - Review. PMID 24568279
Common methods for producing humanized antibodies including framework-homology-based humanization, germline humanization, complementary determining regions (CDR)-homology-based humanization and specificity determining residues (SDR) grafting, as well as advantages and disadvantages of each of these methods and their applications are discussed....
Common methods for producing humanized antibodies including framework-homology-based humanization, germline humanization, comp …
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Jankovic J, et al. JAMA Neurol 2018 - Clinical Trial. PMID 29913017 Free PMC article.
PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed to target aggregated forms of α-synuclein, thereby inhibiting neuron-to-neuron transfer of presumed pathogenic forms of α-synuclein, potentially resulting in neuronal protection and slowing disease progression. ...No antidrug antibodies were detected. Serum PRX002 levels increased in an approximately dose-proportional manner; mean terminal elimination half-life was similar across all doses (10.2 days). ...
PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed to target aggregated forms of α-synuclein, thereby inhibiti …
Monoclonal antibodies in allergy; updated applications and promising trials.
Ozdemir C. Recent Pat Inflamm Allergy Drug Discov 2015 - Review. PMID 25706526
Monoclonal antibodies can be the major actors in this targeting process. Concerns about the safety, efficacy and long-term tolerability of these molecules always stand as a question for them, in order to gain indications for the treatment of allergic disorders. This review includes most recent developments and patents on usage of monoclonal antibodies for the treatment of allergic disorders....
Monoclonal antibodies can be the major actors in this targeting process. Concerns about the safety, efficacy and long-term tol
Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma.
Mitchell PD, et al. Clin Pharmacol Ther 2016 - Review. PMID 26502193
Human(ized) monoclonal antibodies (hMabs) targeting inflammatory pathways are promising therapeutic agents in asthma management. ...
Human(ized) monoclonal antibodies (hMabs) targeting inflammatory pathways are promising therapeutic agents in asthma managemen …
[Monoclonal antibodies for the treatment of multiple sclerosis].
Sánchez-Seco VG, et al. Med Clin (Barc) 2014 - Review. PMID 25732947 Spanish.
However, due to their moderate therapeutic potential in some patients, a broad search was continued to find new and more effective treatment strategies, largely concentrated on monoclonal antibodies (MOAB). ...
However, due to their moderate therapeutic potential in some patients, a broad search was continued to find new and more effective treatment …
Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA, et al. J Pharm Pract 2015 - Review. PMID 26894245
OBJECTIVE: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. ...RESULTS: Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. ...
OBJECTIVE: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for th …
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, et al. Ann Rheum Dis 2017 - Clinical Trial. PMID 27553214 Free PMC article.
OBJECTIVE: To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA). ...
OBJECTIVE: To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind ph …
56,718 results
Jump to page
Feedback